Market Overview

Bovie Medical Corporation Announces Completion of "Core" Business Segment Sale to Symmetry Surgical, Inc. for Total Cash Consideration of $97 Million


Divestiture and Sale of the Core business segment allows the Company
to further focus on the commercialization of Renuvion™ Cosmetic

Bovie Medical Corporation (NYSE:BVX) (the "Company"), a maker
of medical devices and supplies and the developer of J-Plasma®,
a patented surgical product marketed and sold under the Renuvion™
Cosmetic Technology brand in the cosmetic surgery market, today
announced that it has completed the previously announced divestiture and
sale of the Core business segment and the Bovie® brand
to Symmetry Surgical, Inc. for gross proceeds of $97 million in cash.
Bovie Medical shareholders voted to approve the divestiture and sale
transaction at an annual meeting of shareholders held on August 30, 2018.

"The closing of the divestiture and sale of our Core business segment to
Symmetry is an important milestone for our organization as it allows us
to further focus on our strategic objective of commercializing our
J-Plasma technology under the Renuvion brand in the cosmetic surgery
market," said Charlie Goodwin, Chief Executive Officer of the Company.
"We believe this transaction has already created significant value for
our shareholders and positions us to aggressively pursue the extremely
compelling opportunity our Advanced Energy business has in serving the
cosmetic surgery market. We look forward to sharing more details about
the future growth and profitability profile of our Company – as well as
updating our fiscal year 2018 financial guidance – on our corporate
update call on September 5, 2018."

Conference Call Details:

Management will host a conference call at 8:00 a.m. Eastern Time on
September 5, 2018 to discuss the transaction and to host a question and
answer session. To listen to the call by phone, interested parties
within the U.S. may dial 844-507-6493 (or 647-253-8641 for international
callers) and provide access code 9489957. Participants should ask for
the Bovie Medical Corporation Call.

A live webcast of the call will be accessible via the Investor Relations
section of the Company's website and at:

A telephonic replay will be available approximately two hours after the
end of the call through 11:59pm ET on Wednesday 9/19. The replay can be
accessed by dialing 800- 585-8367 for U.S. callers or 416-621-4642 for
International callers and using the replay access code: 9489957. The
webcast will be archived on the Investor Relations section of the
Company's website.

About Bovie Medical Corporation:

Bovie Medical Corporation is a leading maker of medical devices and
supplies as well as the developer of J-Plasma® technology (marketed and
sold under the Renuvion™ Cosmetic Technology brand in the cosmetic
surgery market), a patented plasma-based surgical product for cutting,
coagulation and ablation of soft tissue. J-Plasma technology utilizes a
helium ionization process to produce a stable, focused beam of plasma
that provides surgeons with greater precision, and minimal
invasiveness. The Company also leverages its expertise through original
equipment manufacturing (OEM) agreements with other medical device
manufacturers. For further information about the Company and its
products, please refer to the Bovie Medical Corporation website at

About Symmetry Surgical Inc.:

Symmetry develops and delivers high-quality surgical instrumentation to
healthcare providers around the world. Symmetry's portfolio of more than
20,000 instruments includes proven, trusted brands, and Symmetry works
to bring new innovations to market that can help clinicians deliver
superior patient care – from access to intervention to closure in
surgical procedures. Symmetry's rich and diverse history creates one of
the industry's most comprehensive surgical instrument portfolios, which
includes well-known brands such as BOOKWALTER®, GREENBERG®, OLSEN®,
ROTILT®, SYMMETRY ACCESS™, and VESOCCLUDE®. For more information, please

Cautionary Statement on Forward-Looking

Certain matters discussed in this release and oral statements made from
time to time by representatives of the Company may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and the Federal securities laws. Although
the Company believes that the expectations reflected in such
forward-looking statements are based upon reasonable assumptions, it can
give no assurance that its expectations will be achieved.

Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from
those projected. Many of these factors are beyond the Company's ability
to control or predict. Important factors that may cause actual results
to differ materially and that could impact the Company and the
statements contained in this release can be found in the Company's
filings with the Securities and Exchange Commission including the
Company's Report on Form 10-K for the year ended December 31, 2017 and
subsequent Form 10-Q filings. For forward-looking statements in this
release, the Company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. The Company assumes no obligation to
update or supplement any forward-looking statements whether as a result
of new information, future events or otherwise.

View Comments and Join the Discussion!